Cargando…
A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy
BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a rare pathological type of non-small cell lung cancer, only occurs in 0.1%–0.4 % of lung cancer patients. It has a poor prognosis and shows low response to conventional chemotherapy. Target therapy, immunotherapy, and other new approaches are wor...
Autores principales: | Cai, Ruoxue, Liu, Ying, Sha, Huanhuan, Yu, Jingjing, Fang, Ying, Zhou, Guoren, Shen, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656269/ https://www.ncbi.nlm.nih.gov/pubmed/38027958 http://dx.doi.org/10.1016/j.heliyon.2023.e21902 |
Ejemplares similares
-
Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib—a case report
por: Li, Yu-Feng, et al.
Publicado: (2022) -
Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
por: Zhu, Shibin, et al.
Publicado: (2022) -
Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022) -
Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report
por: Jin, Caibao, et al.
Publicado: (2020) -
Use of PD‐1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report
por: Xu, Li, et al.
Publicado: (2021)